To ask the Secretary of State for Health and Social Care, to ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that Government will not be procuring any doses of Evusheld at this time, if he will (a) provide details of the process that led to that decision, and (b) set out what threshold of evidence for effectiveness he expects to be set for potential future prophylactic Covid-19 treatments.
The decision not to procure Evusheld for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective, enables access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Department intends to publish further details of the clinical advice received shortly.